viewNetscientific PLC

Orderly wind up of Wanda and Vortex

/**/ .h{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.h{}p.o{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align: center}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";}table.p{margin-left:-5.4pt;border-collapse:collapse}td.k{width:307.9pt;padding:0cm 5.4pt 0cm 5.4pt}p.q{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}td.j{width:121.3pt;padding:0cm 5.4pt 0cm 5.4pt} /**/
RNS Number : 1914T
NetScientific PLC
18 March 2019

NetScientific plc

("NetScientific" or the "Company")

Orderly wind up of Wanda and Vortex

Further to its announcement and circular to shareholders ("Circular") on 15 February 2019, NetScientific plc (AIM: NSCI) announces that the directors of each of Vortex Biosciences ("Vortex") and Wanda, Inc. ("Wanda"), which are Portfolio Companies of NetScientific,  have resolved to effect the orderly wind up of those respective companies.

In the Circular, NetScientific had stated that it would allocate the Company's remaining cash to managing its stakes in those Portfolio Companies which the Board believed provided the most realistic prospects of delivering Shareholder returns within the anticipated lifespan of the Company. At that stage, the Board believed those Portfolio Companies would be Glycotest, Inc. ("Glycotest"), ProAxsis Ltd ("ProAxsis") and PDS BioTechnology ("PDS").  

Absent viable additional funding, the Board continues to believe that Glycotest, ProAxsis and PDS provide the most realistic prospects of delivering Shareholder returns within the anticipated lifespan of the Company. Accordingly, having reviewed and considered the cash position of the Company, and any potential additional funding options available to the Company, the Board resolved that it was not in a position to continue to provide financial support to Vortex and Wanda without prejudicing its ability to allocate sufficient cash resources to Glycotest, ProAxsis and PDS.

The Company has received an indicative proposal from a third party regarding the sale of the Company's shareholdings in Wanda and Vortex (the "Potential Disposal"). Having considered the indicative terms of, and taking account of the anticipated timeline to complete and the execution risks of, the Potential Disposal, the Board believes that the level of consideration offered is not sufficient to justify the Company continuing to provide the necessary financial support to Wanda and Vortex whilst due diligence and negotiations regarding the terms of the Potential Disposal are undertaken, without prejudicing the Company's ability to allocate sufficient cash resources to Glycotest, ProAxsis and PDS. The Board has therefore concluded that it was not in the best interests of the Company to proceed with the Potential Disposal.

Subsequently, the directors of Vortex and Wanda respectively resolved to effect the orderly wind up of those companies.

Capitalised terms used in this announcement have the meanings given to them in the Circular sent to Shareholders on 15 February 2019.

The Company anticipates releasing another announcement regarding another Portfolio Company shortly.

For more information, please contact:


François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO    


Tel: +44 (0)20 3514 1800

WH Ireland Limited (NOMAD, Financial Adviser and Broker)

Chris Fielding / Jessica Cave


Tel: +44 (0)20 7220 1666


Consilium Strategic Communications            

Mary-Jane Elliott / Chris Welsh / Laura Thornton

[email protected]

Tel: +44 (0)20 3709 5700



About NetScientific

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases.

For more information, please visit the website at http://www.NetScientific.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Netscientific PLC

Price: 6

Market: AIM
Market Cap: £4.71 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19